Your browser doesn't support javascript.
Lung Transplantation for Severe Post-coronavirus Disease 2019 Respiratory Failure.
Hawkins, Robert B; Mehaffey, J Hunter; Charles, Eric J; Mannem, Hannah C; Roeser, Mark.
  • Hawkins RB; Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, VA.
  • Mehaffey JH; Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, VA.
  • Charles EJ; Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, VA.
  • Mannem HC; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA.
  • Roeser M; Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, VA.
Transplantation ; 105(6): 1381-1387, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1364868
ABSTRACT

BACKGROUND:

The coronavirus disease 2019 (COVID-19) pandemic has resulted in >72 million cases and 1.6 million deaths. End-stage lung disease from COVID-19 is a new and growing entity that may benefit from lung transplant; however, there are limited data on the patient selection, perioperative management, and expected outcomes of transplantation for this indication.

METHODS:

A systematic review of the literature was performed with searches of MEDLINE and Web of Science databases as well as the gray literature. All manuscripts, editorials, commentaries, and gray literature reports of lung transplantation for COVID-related respiratory failure were included. A case from the University of Virginia is described and included in the review.

RESULTS:

A total of 27 studies were included 11 manuscripts, 5 commentaries, and 11 gray literature reports. The total number of transplantations for COVID-related lung disease was 21. The mean age was 55±12 years, 16 (76%) were male individuals, and the acuity was high, with 85% on extracorporeal membrane oxygenation preoperatively. There was a 95% early survival rate, with 1 additional late death. There is growing histopathologic evidence for permanent structural damage with no replicating virus at the time of transplantation.

CONCLUSIONS:

Bilateral lung transplantation is an effective treatment option with reasonable short-term outcomes for patients with end-stage lung failure secondary to COVID-19. However, specific considerations in this new population require a multidisciplinary approach. As we move into the second wave of the COVID-19 global pandemic, lung transplantation will likely have a growing role in management of these complex patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / Lung Transplantation / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Journal: Transplantation Year: 2021 Document Type: Article Affiliation country: TP.0000000000003706

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / Lung Transplantation / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Journal: Transplantation Year: 2021 Document Type: Article Affiliation country: TP.0000000000003706